Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2016
The Mayo Clinic
mi
from
Rochester, MN
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2016
Royal Childrens Hospital
mi
from
Herston,
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2016
Royal Childrens Hospital
mi
from
Herston,
Click here to add this to my saved trials
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Status: Enrolling
Updated:  3/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Status: Enrolling
Updated: 3/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Status: Enrolling
Updated:  3/21/2016
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Status: Enrolling
Updated: 3/21/2016
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Status: Enrolling
Updated:  3/21/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Status: Enrolling
Updated: 3/21/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Status: Enrolling
Updated:  3/21/2016
Rhode Island Hospital
mi
from
Providence, RI
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Status: Enrolling
Updated: 3/21/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/25/2016
Novartis Investigator Site
mi
from
Birmingham, AL
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/25/2016
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/25/2016
Novartis Investigative Site
mi
from
Southaven, MS
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/25/2016
Novartis Investigative Site
mi
from
Southaven, MS
Click here to add this to my saved trials
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/25/2016
Novartis Investigative Site
mi
from
Hiouston, TX
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/25/2016
Novartis Investigative Site
mi
from
Hiouston, TX
Click here to add this to my saved trials
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/25/2016
Novartis
mi
from
San Antonio, TX
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/25/2016
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  3/25/2016
Novartis Investigative Site
mi
from
Morgantown, WV
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 3/25/2016
Novartis Investigative Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
National Cancer Institute
mi
from
Bethesda, MD
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
New York University
mi
from
New York, NY
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
New York University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
University of Rochester School of Medicine and Dentistry
mi
from
Rochester, NY
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
University of Rochester School of Medicine and Dentistry
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
The Ohio Sate University
mi
from
Columbus, OH
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
The Ohio Sate University
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
Univerity of Washington
mi
from
Seattle, WA
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
Univerity of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
University of Wisconsin
mi
from
Madison, WI
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
The Mayo Clinic
mi
from
Rochester, MN
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated:  3/30/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling
Updated: 3/30/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
mi
from
Aurora, CO
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
mi
from
Augusta, GA
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  3/31/2016
Clinical Research Facility
mi
from
Charleston, SC
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 3/31/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
University of Alabama at Birmingham/ Kirklin Clinic Kirklin Clinic
mi
from
Birmingham, AL
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
University of Alabama at Birmingham/ Kirklin Clinic Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
University of California at Los Angeles Dept. of Hematology-Oncology
mi
from
Los Angeles, CA
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
University of California at Los Angeles Dept. of Hematology-Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Florida Academic Dermatology Center
mi
from
Miami, FL
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Florida Academic Dermatology Center
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)
mi
from
Atlanta, GA
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia
mi
from
Augusta, GA
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia
mi
from
Augusta, GA
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept. of NorthwesterUMed
mi
from
Chicago, IL
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept. of NorthwesterUMed
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Indiana University Dept. of IU Cancer Center
mi
from
Indianapolis, IN
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Indiana University Dept. of IU Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Boston Medical Center StudyCoordinator:CLBH589B2201
mi
from
Boston, MA
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Boston Medical Center StudyCoordinator:CLBH589B2201
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(3)
mi
from
Boston, MA
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(3)
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
University of Michigan Health System Michigan HouseClinTrialsOffice
mi
from
Ann Arbor, MI
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
University of Michigan Health System Michigan HouseClinTrialsOffice
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Wake Forest University Baptist Medical Center OutpatientCmprehensivCancerCtr
mi
from
Winston-Salem, NC
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Wake Forest University Baptist Medical Center OutpatientCmprehensivCancerCtr
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
University Dermatology Consultants, Inc.
mi
from
Cincinnati, OH
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
University Dermatology Consultants, Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Oregon Health & Science University Dept. of OHSU Cancer Institute
mi
from
Portland, OR
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Oregon Health & Science University Dept. of OHSU Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
University of Pittsburgh Medical Center, Department of Dermatology
mi
from
Pittsburgh, PA
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
University of Pittsburgh Medical Center, Department of Dermatology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
MD Anderson Cancer Center/University of Texas StudyCoordinator:CLBH589B2201
mi
from
Houston, TX
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
MD Anderson Cancer Center/University of Texas StudyCoordinator:CLBH589B2201
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/2/2016
Novartis Investigative Site
mi
from
Caba,
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/2/2016
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
University of California at Davis Center for Aids Research and Education Services
mi
from
Sacramento, CA
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
University of California at Davis Center for Aids Research and Education Services
mi
from
Sacramento, CA
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials